What is Grace Therapeutics, Inc's earnings per share (EPS)?

Grace Therapeutics, Inc (GRCE) reported diluted earnings per share of -$0.47 for fiscal year 2026. This represents a 40.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Grace Therapeutics, Inc (GRCE) Financials

GRCE

FY2026 annual

Revenue Not reported for FY2026

Net Income -$7.8M +18.6% YoY

EPS (Diluted) -$0.47 +40.5% YoY

Operating Cash Flow -$8.9M +40.5% YoY

Market Cap $45.0M as of Sep 3, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2026

Price / Book 0.9x on $48.2M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GRCE SEC filings page.

This page shows Grace Therapeutics, Inc (GRCE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GRCE FY2026 2026-08-30

Grace Therapeutics is a cash-consuming research business, with losses narrowing while financing still supports the balance sheet.

From FY2025 to FY2026, operating cash flow improved from -$14.9M to -$8.9M, while net loss narrowed less sharply. The smaller gap between cash use and reported loss means earnings more closely tracked funding needs in FY2026 than in FY2025.

The operating loss fell from -$16.7M to -$11.1M between FY2025 and FY2026, but later-year revenue is not reported, so the improvement cannot be attributed to scale or margin expansion. R&D spending dropped from $9.5M to $2.4M, indicating that lower costs—not demonstrated sales growth— drove much of the improvement. SG&A rose from $7.2M to $8.7M, shifting the expense mix toward administration.

The balance sheet became less debt-dependent: total liabilities fell from $5.4M to $2.8M between FY2025 and FY2026. Debt-to-equity was 0.1x in FY2025 and 0.0x in FY2026, while financing cash inflows of $14.0M in FY2025 and $3.7M in FY2026 arrived alongside negative operating cash flow. That combination points to operations being funded externally rather than by internally generated cash.

Financial Health Signals

Financial health score not available

Grace Therapeutics, Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Grace Therapeutics, Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Grace Therapeutics, Inc reported a net loss of $7.8M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$15.9M

YoY-415.4%

Grace Therapeutics, Inc's EBITDA was -$15.9M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 415.4% from the same quarter a year earlier.

Net Income

-$15.8M

YoY-369.7%

Grace Therapeutics, Inc reported -$15.8M in net income in Q1 2027. This represents a decrease of 369.7% from the same quarter a year earlier.

EPS (Diluted)

-$0.91

YoY-333.3%

QoQ-1416.7%

Grace Therapeutics, Inc earned -$0.91 per diluted share (EPS) in Q1 2027. This represents a decrease of 333.3% from the same quarter a year earlier. Against the prior quarter it is down 1416.7%.

Revenue

Not reported for Q1 2027.

Cash & Balance Sheet

Cash & Debt

$13.8M

YoY-31.2%

QoQ-19.0%

5Y CAGR-19.6%

Grace Therapeutics, Inc held $13.8M in cash as of Q1 2027; long-term debt is not reported for that period.

Shares Outstanding

21M

YoY+52.1%

QoQ+29.3%

5Y CAGR-36.8%

Grace Therapeutics, Inc had 21M shares outstanding in Q1 2027. This represents an increase of 52.1% from the same quarter a year earlier. Against the prior quarter it is up 29.3%.

Free Cash Flow

Not reported for Q1 2027.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Return on Equity

-32.8%

YoY-27.5pp

Grace Therapeutics, Inc's ROE was -32.8% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is down 27.5 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2027.

Operating Margin

Not reported for Q1 2027.

Net Margin

Not reported for Q1 2027.

Capital Allocation

R&D Spending

$697K

YoY-27.0%

Grace Therapeutics, Inc invested $697K in research and development in Q1 2027. This represents a decrease of 27.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2027.

Capital Expenditures

Not reported for Q1 2027.

GRCE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GRCE quarterly income statement

Metric	TTM	FY26DEF 14A	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Revenue	N/A	N/A	N/A	N/A	N/A	$100.0M+50920.4%	$196K	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$76K	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	$100.0M+83233.3%	$120K	N/A	N/A
R&D Expenses	N/A	$2.4M-74.7%	$9.5M+103.1%	$4.7M-53.0%	$10.0M+79.4%	$5.6M+33.2%	$4.2M-73.9%	$16.0M-45.6%	$29.4M
SG&A Expenses	N/A	$8.7M+21.0%	$7.2M+7.2%	$6.7M-12.2%	$7.6M-17.8%	$9.3M+67.8%	$5.5M-4.8%	$5.8M+27.8%	$4.5M
Operating Income	N/A	-$11.1M+33.6%	-$16.7M-29.8%	-$12.9M+75.4%	-$52.2M-234.6%	-$15.6M+5.1%	-$16.4M+32.8%	-$24.4M+29.0%	-$34.4M
EBITDA	N/A	-$11.1M+33.6%	-$16.7M-29.8%	-$12.8M+75.3%	-$52.0M-233.8%	-$15.6M-0.6%	-$15.5M+29.9%	-$22.1M+31.0%	-$32.1M
Income Tax	N/A	-$1.7M+46.9%	-$3.2M-74.6%	-$1.8M+80.8%	-$9.5M-1372.5%	-$648K	$0	$0	$0
Net Income	N/A	-$7.8M+18.6%	-$9.6M+25.6%	-$12.9M+69.7%	-$42.4M-332.1%	-$9.8M+50.1%	-$19.7M+22.9%	-$25.5M+35.2%	-$39.4M
EPS (Basic)	N/A	-$0.47+40.5%	-$0.79+41.5%	-$1.35+76.4%	-$5.71-2014.8%	-$0.27	N/A	N/A	N/A
EPS (Diluted)	-$1.17	-$0.47+40.5%	-$0.79+41.5%	-$1.35	-$5.71	-$0.27	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	17M+36.6%	12M+26.8%	10M	7M	37M	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
R&D Expenses	$697K-27.0%	N/A	$462K-78.9%	$568K-80.9%	$955K-64.7%	N/A	$2.2M+52.0%	$3.0M+547.0%
SG&A Expenses	$1.7M-21.0%	N/A	$2.0M+31.6%	$2.0M+5.7%	$2.1M-5.3%	N/A	$1.5M-5.6%	$1.9M+13.7%
Operating Income	-$15.9M-415.1%	N/A	-$2.4M+33.9%	-$2.5M+47.7%	-$3.1M+37.7%	N/A	-$3.7M-21.7%	-$4.8M-130.9%
EBITDA	-$15.9M-415.4%	N/A	-$2.4M+33.9%	-$2.5M+47.6%	-$3.1M+37.8%	N/A	-$3.7M-21.7%	-$4.8M-131.1%
Income Tax	$0	N/A	$0+100.0%	$0+100.0%	$0+100.0%	N/A	-$605K-190.9%	-$852K-91.0%
Net Income	-$15.8M-369.7%	N/A	-$2.3M+44.3%	-$938K+72.7%	-$3.4M-28.5%	N/A	-$4.2M-73.8%	-$3.4M-4.9%
EPS (Basic)	-$0.91-333.3%	-$0.06-160.0%	-$0.14+61.1%	-$0.06+80.0%	-$0.21+12.5%	$0.10+138.5%	-$0.36-71.4%	-$0.30+30.2%
EPS (Diluted)	-$0.91-333.3%	-$0.06-160.0%	-$0.14+61.1%	-$0.06+80.0%	-$0.21+12.5%	$0.10+138.5%	-$0.36-71.4%	-$0.30
Diluted Shares (Avg)	17M+8.4%	N/A	17M+47.2%	16M+38.4%	16M+45.7%	N/A	12M0.0%	12M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

GRCE Balance Sheet

GRCE quarterly balance sheet

Metric	FY26DEF 14A	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Total Assets	$66.7M-7.4%	$72.0M-1.8%	$73.3M-7.4%	$79.1M-38.5%	$128.6M+105.9%	$62.5M+173.3%	$22.9M-38.1%	$36.9M
Current Assets	$17.4M-23.5%	$22.7M-5.4%	$24.0M-18.0%	$29.3M-35.3%	$45.3M-27.4%	$62.4M+237.8%	$18.5M-34.0%	$28.0M
Cash & Equivalents	$17.0M-23.3%	$22.1M-3.8%	$23.0M-17.5%	$27.9M-8.1%	$30.3M-40.4%	$50.9M+257.7%	$14.2M-15.6%	$16.9M
Short-Term Investments	$0	$0	$0-100.0%	$15K-99.9%	$13.3M+36.1%	$9.8M	$0-100.0%	$8.9M
Accounts Receivable	N/A	N/A	$722K-10.0%	$802K+46.4%	$548K+3.4%	$530K-2.9%	$546K-54.1%	$1.2M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$20K
Goodwill	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M-37.2%	$13.0M	N/A	N/A	N/A
Total Liabilities	$2.8M-48.8%	$5.4M-53.4%	$11.6M+3.5%	$11.2M-45.1%	$20.4M+199.4%	$6.8M-31.0%	$9.9M-61.9%	$25.9M
Current Liabilities	$2.1M+11.2%	$1.9M+14.6%	$1.7M-50.6%	$3.4M+4.6%	$3.3M+106.5%	$1.6M-78.6%	$7.4M-45.9%	$13.7M
Non-Current Liabilities	$612K-82.3%	$3.5M-65.0%	$9.9M+27.3%	$7.8M-54.6%	$17.1M+227.5%	$5.2M+111.8%	$2.5M-79.8%	$12.2M
Total Equity	$63.9M-4.1%	$66.6M+7.9%	$61.7M-9.1%	$68.0M-37.2%	$108.3M+94.5%	$55.7M+328.4%	$13.0M+17.6%	$11.0M
Retained Earnings	-$228.5M-3.5%	-$220.7M-4.5%	-$211.1M-6.5%	-$198.3M-27.2%	-$155.8M-6.7%	-$146.0M-15.6%	-$126.3M-25.3%	-$100.8M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$50.1M-28.3%	$66.7M-7.4%	$68.5M+11.9%	$66.6M+1.9%	$69.8M+0.1%	$72.0M-1.8%	$61.2M-19.6%	$65.3M-16.4%
Current Assets	$14.3M-30.2%	$17.4M-23.5%	$19.2M+60.9%	$17.3M+7.7%	$20.5M+0.5%	$22.7M-5.4%	$11.9M-55.6%	$16.1M-44.4%
Cash & Equivalents	$13.8M-31.2%	$17.0M-23.3%	$18.7M+68.9%	$16.9M+11.3%	$20.0M+3.2%	$22.1M-3.8%	$11.1M-40.4%	$15.2M-43.9%
Short-Term Investments	$0	$0	$0	$0-100.0%	$0-100.0%	$0	$0-100.0%	$15K0.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%	$8.1M0.0%
Total Liabilities	$1.9M-70.2%	$2.8M-48.8%	$3.6M-60.4%	$3.8M-59.2%	$6.3M-39.6%	$5.4M-53.4%	$9.1M-21.0%	$9.2M-19.6%
Current Liabilities	$1.3M-46.0%	$2.1M+11.2%	$1.3M-34.9%	$1.2M-53.4%	$2.3M-11.0%	$1.9M+14.6%	$2.0M+11.4%	$2.7M+91.4%
Non-Current Liabilities	$612K-84.5%	$612K-82.3%	$2.3M-67.5%	$2.5M-61.6%	$3.9M-49.2%	$3.5M-65.0%	$7.1M-26.9%	$6.5M-35.0%
Total Equity	$48.2M-24.1%	$63.9M-4.1%	$64.9M+24.5%	$62.8M+11.9%	$63.5M+7.1%	$66.6M+7.9%	$52.1M-19.4%	$56.1M-15.9%
Retained Earnings	-$244.3M-9.0%	-$228.5M-3.5%	-$227.3M-2.7%	-$225.0M-3.6%	-$224.0M-4.8%	-$220.7M-4.5%	-$221.3M-6.4%	-$217.2M-5.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

GRCE Cash Flow Statement

GRCE quarterly cash flow statement

Metric	TTM	FY26DEF 14A	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Operating Cash Flow	-$10.3M	-$8.9M+40.5%	-$14.9M-20.8%	-$12.3M+22.5%	-$15.9M+7.7%	-$17.2M-20.4%	-$14.3M+37.6%	-$23.0M	N/A
Depreciation & Amortization	N/A	$7K0.0%	$7K-36.4%	$11K-91.1%	$124K	$0-100.0%	$924K-60.2%	$2.3M-0.6%	$2.3M
Stock-Based Compensation	N/A	$798K+9.3%	$730K-20.0%	$913K-49.6%	$1.8M+35.5%	$1.3M+13.9%	$1.2M-39.9%	$2.0M	N/A
Investing Cash Flow	N/A	$0	$0-100.0%	$104K-99.2%	$13.2M+473.5%	-$3.5M+64.3%	-$9.9M-221.1%	$8.1M	N/A
Financing Cash Flow	$4.0M	$3.7M-73.5%	$14.0M+90.7%	$7.4M+2320.7%	$304K	$0-100.0%	$59.5M+351.3%	$13.2M	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	-$3.2M-78.8%	-$1.7M+42.6%	-$2.2M+45.8%	-$3.1M+25.9%	-$1.8M+49.9%	-$3.0M-41.5%	-$4.1M-117.5%	-$4.2M-100.6%
Depreciation & Amortization	$2K0.0%	$2K0.0%	$3K+50.0%	$0-100.0%	$2K+100.0%	$2K+100.0%	$2K+100.0%	$2K0.0%
Stock-Based Compensation	$105K-65.2%	N/A	N/A	N/A	$302K+26.9%	N/A	N/A	N/A
Investing Cash Flow	N/A	$0	$0-100.0%	$0	$0+100.0%	$0-100.0%	$15K+100.2%	$0-100.0%
Financing Cash Flow	$0+100.0%	$0-100.0%	$4.0M	$0	-$327K	$14.0M	$0	$0-100.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

GRCE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GRCE quarterly financial ratios

Metric	FY26DEF 14A	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Gross Margin	N/A	N/A	N/A	N/A	100.0%+38.8pp	61.2%	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	-15.6%	-8377.0%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	-9.8%	-10039.8%	N/A	N/A
Return on Equity	-12.2%+2.2pp	-14.4%+6.5pp	-20.8%+41.6pp	-62.4%-53.4pp	-9.1%+26.3pp	-35.4%+161.0pp	-196.3%+160.1pp	-356.4%
Return on Assets	-11.7%+1.6pp	-13.3%+4.2pp	-17.5%+36.1pp	-53.6%-46.0pp	-7.6%+23.9pp	-31.5%+80.1pp	-111.6%-5.0pp	-106.7%
Current Ratio	8.10-3.7x	11.77-2.5x	14.26+5.7x	8.59-5.3x	13.89-25.6x	39.50+37.0x	2.50+0.5x	2.05
Debt-to-Equity	0.040.0x	0.08-0.1x	0.190.0x	0.160.0x	0.19+0.1x	0.12-0.6x	0.76-1.6x	2.34
Asset Turnover	N/A	N/A	N/A	N/A	0.78+0.8x	0.00	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Return on Equity	-32.8%-27.5pp	N/A	-3.6%+4.4pp	-1.5%+4.6pp	-5.3%-0.9pp	N/A	-8.0%-4.3pp	-6.1%-1.2pp
Return on Assets	-31.5%-26.7pp	N/A	-3.4%+3.4pp	-1.4%+3.8pp	-4.8%-1.1pp	N/A	-6.8%-3.7pp	-5.3%-1.1pp
Current Ratio	11.47+2.6x	8.10-3.7x	14.96+8.9x	13.89+7.9x	8.87+1.0x	11.77-2.5x	6.06-9.1x	6.01-14.7x
Debt-to-Equity	0.04-0.1x	0.040.0x	0.06-0.1x	0.06-0.1x	0.10-0.1x	0.08-0.1x	0.170.0x	0.160.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Grace Therapeutics, Inc GRCE	FY2026	N/A	-$7.8M	N/A	$45.0M	—
Plus Therapeutics Inc PSTV	FY2025	$5.2M	-$22.4M	N/A	$26.6M	31/100
Verrica Pharmaceuticals VRCA	FY2025	$35.6M	-$17.9M	-50.3%	$90.0M	68/100
PepGen Inc PEPG	FY2025	N/A	-$89.7M	N/A	$216.1M	—
Annovis Bio Inc ANVS	FY2025	$0	-$28.9M	N/A	$72.0M	—
Barinthus Biotherapeutics plc BRNS	FY2025	$0	-$66.4M	N/A	$31.2M	—

Where Grace Therapeutics, Inc Ranks

Frequently Asked Questions

Is Grace Therapeutics, Inc profitable?

No, Grace Therapeutics, Inc (GRCE) reported a net income of -$7.8M in fiscal year 2026.

What is Grace Therapeutics, Inc's EBITDA?

Grace Therapeutics, Inc (GRCE) had EBITDA of -$11.1M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Grace Therapeutics, Inc's return on equity (ROE)?

Grace Therapeutics, Inc (GRCE) has a return on equity of -12.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Grace Therapeutics, Inc's operating cash flow?

Grace Therapeutics, Inc (GRCE) recorded an outflow of $8.9M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are Grace Therapeutics, Inc's total assets?

Grace Therapeutics, Inc (GRCE) had $66.7M in total assets as of fiscal year 2026, including both current and long-term assets.

How much does Grace Therapeutics, Inc spend on research and development?

Grace Therapeutics, Inc (GRCE) invested $2.4M in research and development during fiscal year 2026.

How many shares does Grace Therapeutics, Inc have outstanding?

Grace Therapeutics, Inc (GRCE) had 16M shares outstanding as of fiscal year 2026.

What is Grace Therapeutics, Inc's current ratio?

Grace Therapeutics, Inc (GRCE) had a current ratio of 8.10 as of fiscal year 2026, which is generally considered healthy.

What is Grace Therapeutics, Inc's debt-to-equity ratio?

Grace Therapeutics, Inc (GRCE) had a debt-to-equity ratio of 0.04 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Grace Therapeutics, Inc's return on assets (ROA)?

Grace Therapeutics, Inc (GRCE) had a return on assets of -11.7% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Grace Therapeutics, Inc's P/E ratio?

Grace Therapeutics, Inc (GRCE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $45.0M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Grace Therapeutics, Inc's price-to-sales ratio?

Grace Therapeutics, Inc (GRCE) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $45.0M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Grace Therapeutics, Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, Grace Therapeutics, Inc (GRCE) held $17.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.9M over that year. Dividing the one by the other, the reported balance equals about 23 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Grace Therapeutics, Inc's Piotroski F-Score?

Grace Therapeutics, Inc (GRCE) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Grace Therapeutics, Inc's earnings high quality?

Grace Therapeutics, Inc (GRCE) reported a net loss of $7.8M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.